Walleye Capital
TRVI icon

Walleye Capital’s Trevi Therapeutics TRVI Stock Holding History

Walleye Capital’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-33,097
Closed -$136K – 5145
2024
Q4 		$136K Buy
+33,097
New +$106K ﹤0.01% 3978

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Walleye Capital's TRVI Position: Q1 2025 in Review

Walleye Capital sold out of Trevi Therapeutics (TRVI) in Q1 2025, closing a stake of 33,097 shares — an estimated $136K sold.

Walleye Capital first reported a position in TRVI in Q4 2024 and held it in 1 quarter. The position peaked at $136K in Q4 2024. 137 funds tracked by Wall St. Rank hold TRVI as of Q1 2025.

  • Walleye Capital reported no remaining Trevi Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Walleye Capital sold 33,097 Trevi Therapeutics shares in Q1 2025, an estimated $136K.
  • Walleye Capital first reported a position in Trevi Therapeutics in Q4 2024 and held it in 1 quarter.
  • Walleye Capital's Trevi Therapeutics position peaked at $136K in Q4 2024.
  • 137 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2025.

Based on Walleye Capital's 13F filing for Q1 2025, filed 14 May 2025.